Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy

Inclusion Criteria

• •1. The participants must be female and 18 years of age or older.
• •2. Resectable invasive adenocarcinoma of the breast, confirmed histologically.
• •3. Ductal carcinoma in situ confirmed histologically.
• •4. The participants must be a preoperative clinical Tis, T1, T2, T3 as well as clinical M0 breast cancer.
• •5. Without clinical or radiological nodal involvement (cN0): No positive ipsilateral axillary lymph nodes; No prior removal of ipsilateral axillary lymph nodes; No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy.
• •6. With clinical positive lymph nodes (cN1) (including any abnormal or enlarged clinically palpable lymph nodes or core biopsy/surgical biopsy/FNA evidence of malignant cell within any lymph nodes) that was downstaged to cN0 following neoadjuvant therapy.
• •7. The participants must have an ECOG performance status of Grade 0-1.
• •8. The participants must provide written informed consent before participating in the study.